Inhibition of Ovulation, Patch, Ethinylestradiol and Gestodene

PHASE2TerminatedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions
ContraceptionOvulation Inhibition
Interventions
DRUG

Ethinylestradiol/Gestodene (BAY86-5016)

transdermal patch: 0.55mg EE+2.1mg GSD; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles)

DRUG

Ethinylestradiol/Gestodene (BAY86-5016)

transdermal patch: 0.55mg EE+1.05 mg GSD; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles

Trial Locations (3)

10115

Berlin

10707

Berlin

13342

Berlin

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY